{"id":44784,"date":"2025-10-30T11:35:27","date_gmt":"2025-10-30T11:35:27","guid":{"rendered":"https:\/\/quickassetsmarket.com\/index.php\/2025\/10\/30\/obesity-drug-rivalry-heats-up-as-novo-nordisk-tops-pfizers-bid-for-metsera\/"},"modified":"2025-10-30T11:35:27","modified_gmt":"2025-10-30T11:35:27","slug":"obesity-drug-rivalry-heats-up-as-novo-nordisk-tops-pfizers-bid-for-metsera","status":"publish","type":"post","link":"https:\/\/quickassetsmarket.com\/index.php\/2025\/10\/30\/obesity-drug-rivalry-heats-up-as-novo-nordisk-tops-pfizers-bid-for-metsera\/","title":{"rendered":"Obesity drug rivalry heats up as Novo Nordisk tops Pfizer\u2019s bid for Metsera"},"content":{"rendered":"
<\/div>\n

In a move that highlights the escalating battle for dominance in the global weight-loss treatment market, Danish pharmaceutical giant Novo Nordisk A\/S has made an improved takeover offer for US-based biotech start-up Metsera Inc.<\/p>\n

The renewed proposal<\/a> aims to beat Pfizer Inc.\u2019s earlier acquisition agreement and strengthen Novo\u2019s position in a market projected to reach $100 billion by 2030.<\/p>\n

It follows Pfizer\u2019s September agreement to acquire the start-up for $47.50 per share\u2014an enterprise value of $4.9 billion\u2014with an additional $22.50 per share contingent on performance milestones. <\/p>\n

Metsera\u2019s shares, which have tripled in 2025, closed at $52.21 on Wednesday, giving the company a market value of about $5.5 billion. <\/p>\n

The stock jumped nearly 19% in pre-market trading on Thursday after news of Novo\u2019s higher offer. <\/p>\n

Pfizer shares remained little changed, while Novo Nordisk\u2019s stock fell as much as 1.5% in Copenhagen.<\/p>\n

Pfizer faces new competition amid declining pandemic sales<\/h2>\n

For Pfizer, the move represents an unexpected challenge as it seeks to rebuild growth after declining demand for its Covid-19 vaccine. <\/p>\n

The US drugmaker has been looking to diversify its portfolio as several of its key products approach the end of their patent lives. <\/p>\n

Pfizer’s own experimental obesity pill was scrapped earlier this year after a patient in clinical trials showed signs of liver injury, leaving the company with limited options in the weight-management space.<\/p>\n

If Novo Nordisk secures Metsera, it would deal a setback to Pfizer\u2019s plans to regain momentum in the post-pandemic era. <\/p>\n

The acquisition would have given Pfizer a foothold in one of the most competitive and profitable therapeutic areas in modern medicine.<\/p>\n

Metsera\u2019s amylin drugs could redefine weight-loss therapy<\/h2>\n

Metsera is among a new generation of biotechnology firms developing alternatives to GLP-1-based drugs such as Novo Nordisk\u2019s Wegovy and Eli Lilly\u2019s Zepbound. <\/p>\n

The company\u2019s lead drug candidate is a long-acting amylin analogue\u2014part of a class that may offer fewer gastrointestinal side effects like nausea and vomiting, which are commonly reported with GLP-1 drugs.<\/p>\n

Metsera\u2019s drug candidates are designed to be administered less frequently than the current market-leading weekly injections, potentially improving patient compliance. <\/p>\n

Such innovation could redefine weight-loss therapy and help major pharmaceutical companies capture new segments of the expanding obesity-treatment market.<\/p>\n

The competition for next-generation weight-loss drugs has intensified sharply as drugmakers seek to secure the next major breakthrough. <\/p>\n

Global demand for effective obesity therapies continues to grow, with analysts estimating that annual sales across the sector could exceed $100 billion by the end of the decade.<\/p>\n

Novo Nordisk\u2019s internal shake-up and strategic push<\/h2>\n

Novo Nordisk\u2019s pursuit of Metsera comes at a time of significant transition within the company. <\/p>\n

Earlier this month, more than half of Novo\u2019s board, including chairman Helge Lund, stepped down following internal disagreements about the pace of corporate change.<\/p>\n

Former CEO Lars Rebien Sorensen, who now chairs the company\u2019s largest shareholder foundation, has returned to take over as chairman.<\/p>\n

The leadership changes are part of a wider restructuring aimed at revitalising the company\u2019s \u201cperformance culture\u201d and reclaiming its edge in the United States, its most critical market. <\/p>\n

Novo has also replaced its chief executive this year as it seeks to maintain its lead in the weight-loss segment against aggressive competition from Eli Lilly.<\/p>\n

Novo Nordisk\u2019s existing flagship product, Wegovy, and its diabetes counterpart, Ozempic, have transformed the company into one of Europe\u2019s most valuable firms. <\/p>\n

However, the success has drawn political and regulatory scrutiny. <\/p>\n

US President Donald Trump recently announced plans to lower the cost of Ozempic to $150 a month, adding further pressure on drugmakers to manage pricing and profitability.<\/p>\n

The post Obesity drug rivalry heats up as Novo Nordisk tops Pfizer\u2019s bid for Metsera<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

In a move that highlights the escalating battle for dominance in the global weight-loss treatment market, Danish pharmaceutical giant Novo Nordisk A\/S has made an improved takeover offer for US-based biotech start-up Metsera Inc. The renewed proposal aims to beat Pfizer Inc.\u2019s earlier acquisition agreement and strengthen Novo\u2019s position in a market projected to reach <\/p>\n","protected":false},"author":1,"featured_media":44785,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":{"0":"post-44784","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"_links":{"self":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/44784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/comments?post=44784"}],"version-history":[{"count":0,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/44784\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media\/44785"}],"wp:attachment":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media?parent=44784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/categories?post=44784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/tags?post=44784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}